Form 4 for PCVX Vaxcyte, Inc.
Accepted 2021-11-22 00:00:00 ET · period of report 2021-11-18 · accession 0001209191-21-066126 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2021-11-22 | 2021-11-18 | PCVX | GUGGENHIME ANDREW | Pres, CFO | S - Sale+OE | $24.53 | -3,100 | 3,240 | -49% | -$76.0K |
| D | 2021-11-22 | 2021-11-18 | PCVX | GUGGENHIME ANDREW | Pres, CFO | M - OptEx | $5.35 | +3,100 | 6,225 | +99% | +$16.6K |
| D | 2021-11-22 | 2021-11-18 | PCVX | GUGGENHIME ANDREW | Pres, CFO | M - OptEx | $0.00 | -3,100 | 521.5K | -0.6% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-11-18 | S | D | 115 | $25.20 | 3,125 | D | — | — | (F4) The price reported is a weighted-average price. The shares were sold at prices ranging from $25.08 to $25.28. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. (F1) Includes shares acquired under the Vaxcyte, Inc. employee stock purchase plan on November 17, 2020 of 1,562 shares and May 17, 2021 of 1,563 shares. |
| 2 | Common | Common Stock | 2021-11-18 | S | D | 2,985 | $24.50 | 3,240 | D | — | — | (F3) The price reported is a weighted-average price. The shares were sold at prices ranging from $24.04 to $24.86. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. (F1) Includes shares acquired under the Vaxcyte, Inc. employee stock purchase plan on November 17, 2020 of 1,562 shares and May 17, 2021 of 1,563 shares. |
| 3 | Common | Common Stock | 2021-11-18 | M | A | 3,100 | $5.35 | 6,225 | D | — | — | (F1) Includes shares acquired under the Vaxcyte, Inc. employee stock purchase plan on November 17, 2020 of 1,562 shares and May 17, 2021 of 1,563 shares. |
| 4 | Derivative | Stock Option (right to buy) | 2021-11-18 | M | D | 3,100 | $0.00 | 521,518 | D | $5.35 · — to 2030-05-11 | 3,100 Common Stock | (F5) 1/4 of the shares subject to the option vested on May 1, 2021, and 1/48 of the shares vest monthly thereafter. |